Semaglutide may raise risk for nonarteritic anterior ischemic optic neuropathy in diabetes
For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...
Medical Dialogues17h
Long-Acting GLP-1RAs Lower Cardiovascular, Kidney Risks and Mortality in Type 2 Diabetes, Meta-Analysis Finds
UK: A systematic review and meta-analysis of randomized trials have highlighted the significant benefits of long-acting ...
Semaglutide reduces risk of cardiovascular events in patients with type 2 diabetes, finds study
Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...
MPR4d
Semaglutide Improves Walking Ability in T2D Patients With Peripheral Artery Disease
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
Medical Dialogues4d
Oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes, suggests study
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Applied Clinical Trials Online5d
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...
Applied Clinical Trials Online6d
API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
PharmExec7d
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Pharmabiz7d
Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC’s annual scientific session
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
Medscape7d
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
News-Medical.Net7d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
ConsumerAffairs8d
Oral Semaglutide (GLP-1) may reduce heart attack, stroke risk in diabetes patients
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...